Background/Aim: It is significant for patients with traumatic brain injury (TBI) to receive prehospital emergency treatment as early as possible to reduce mortality. Therefore, a new prefilled multi-drug injector was developed to improve the treatment of TBI. Here, we studied the pharmacokinetics of dexamethasone (DXM) and nefopam using the injector to investigate the significance of drug interactions and the necessity of dose adjustment. Methods: Rats were administered DXM and nefopam intramuscularly alone or in combination using the injector. The concentrations of DXM and nefopam were measured by means of HPLC. The noncompartmental approach was used to calculate pharmacokinetic parameters. Results: All animals appeared to tolerate the injection very well. The maximum concentration 90% confidence interval (CI) of nefopam was in the bioequivalence range when nefopam was co-administered with DXM. However, the AUC 90% CI of nefopam was out of the range. A statistically significant alteration was also observed in the clearance of nefopam. The co-administration exhibited no significant influence on the pharmacokinetic parameters of DXM. Conclusions: These results indicate that the co-administration of DXM and nefopam using the prefilled multi-drug injector significantly alters some pharmacokinetic parameters of nefopam and has a minor effect on DXM pharmacokinetics.

Keywords:
Dexamethasone, Nefopam, Pharmacokinetics, Multi-drug injector
1.
Guidelines for the Management of Severe Traumatic Brain Injury, ed 3. J Neurotrauma 2007;24:s1-s106.
2.
Risdall JE, Menon DK: Traumatic brain injury. Philos Trans R Soc Lond B Biol Sci 2011;366:241-250.
3.
National Center for Injury Prevention and Control: Facts about Traumatic Brain Injury. September 2006. www.cdc.gov/ncipc/tbi/TBI.htm.
4.
Badjatia N, Carney N, Crocco TJ, Fallat ME, Hennes HM, Jagoda AS, et al: Guidelines for prehospital management of traumatic brain injury. Prehosp Emerg Care 2008;12:S1-S52.
5.
Margulies S, Hicks R; Combination Therapies for Traumatic Brain Injury Workshop Leaders: Combination therapies for traumatic brain injury: prospective considerations. J Neurotrauma 2009;26:925-939.
6.
Jeanneteau F, Garabedian MJ, Chao MV: Activation of Trk neurotrophin receptors by glucocorticoids provides a neuroprotective effect. Proc Natl Acad Sci USA 2008;105:4862-4867.
7.
Campolo M, Ahmad A, Crupi R, Impellizzeri D, Morabito R, Esposito E, et al: Combination therapy with melatonin and dexamethasone in a mouse model of traumatic brain injury. J Endocrinol 2013;217:291-301.
8.
Nichols NR, Agolley D, Zieba M, Bye N: Glucocorticoid regulation of glial responses during hippocampal neurodegeneration and regeneration. Brain Res Brain Res Rev 2005;48:287-301.
9.
Bhatt AM, Pleuvry BJ, Maddison SE: Respiratory and metabolic effects of oral nefopam in human volunteers. Br J Clin Pharmacol 1981;11:209-211.
10.
Piercey MF, Schroeder LA: Spinal and supraspinal sites for morphine and nefopam analgesia in the mouse. Eur J Pharmacol 1981;74:135-140.
11.
Sunshine A, Laska E: Nefopam and morphine in man. Clin Pharmacol Ther 1975;18:530-534.
12.
Johnson B, Adams L, Lu E, Zhang K, Lebowitz P, Lates C, et al: Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone. Support Care Cancer 2009;17:1177-1185.
13.
Abbara C, Rousseau JM, Lelièvre B, Turcant A, Lallement G, Ferec S, et al: Pharmacokinetic analysis of pralidoxime after its intramuscular injection alone or in combination with atropine-avizafone in healthy volunteers. Br J Pharmacol 2010;161:1857-1867.
14.
Loane DJ, Faden AI: Neuroprotection for traumatic brain injury: translational challenges and emerging therapeutic strategies. Trends Pharmacol Sci 2010;31:596-604.
15.
Spanakis M, Vizirianakis IS, Batzias G, Niopas I: Pharmacokinetic interaction between losartan and Rhodiola rosea in rabbits. Pharmacology 2013;91:112-116.
16.
Ziemba R: Use of individual auto-injector kits ‘IZAS-05' on the contemporary battlefield. Med Sci Monit 2012;18:SR1-SR8.
17.
Franklin MR: Drug absorption, action, and disposition; in Gennaro AR (ed): Remington's Pharmaceutical Sciences. Easton, Mack Publishing, 1995, pp 697-723.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.